<div id="readability-page-1">New insider activity at Cosmos Holdings ( (COSM) ) has taken place on January 21, 2026.<h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul> Cosmos Holdings has seen a notable insider buy, as CEO Grigorios Siokas purchased 353,321 shares of the company’s stock in a recent transaction. The acquisition, valued at $173,127, signals a significant show of confidence from the chief executive in the future prospects of Cosmos Holdings. Investors often track such insider activity closely, interpreting sizable personal investments by top leadership as a positive indicator for the company’s outlook. Recent Updates on COSM stock In the last 24 hours, Cosmos Health’s stock activity has been driven mainly by operational and strategic updates rather than explicit analyst actions. The company reported strong growth at its Greek distribution subsidiary Cosmofarm, which added nearly 100 new pharmacy customers in 2025, significantly expanding its active customer base and improving revenue and profitability per customer through better route density, optimized order execution, and operating leverage. Management also highlighted continued investment in logistics automation, including expanded ROWA and A‑frame robotic systems and a new $1 million capital program intended to materially increase processing capacity and support substantial incremental revenue potential. Separately, subsidiary Cana Laboratories entered a multi‑year manufacturing and supply agreement to produce the pharmaceutical product PathMuscle for Libytec Pharmaceutical, with firm minimum production volumes and anticipated multi‑year unit demand, underscoring more visible and recurring revenue prospects. These developments collectively emphasize enhanced growth visibility, margin improvement, and operating efficiency, which are the types of factors that typically drive analysts to revisit valuation assumptions and adjust their outlooks or price targets, even though specific target figures or recommendations were not disclosed in the articles. Spark’s Take on COSM Stock According to Spark, TipRanks’ AI Analyst, COSM is a Underperform. The score is driven primarily by weak financial performance (losses and negative cash flow) and bearish technicals (below key moving averages with negative MACD). Valuation is constrained by unprofitability (negative P/E), and the Nasdaq non-compliance notice adds additional downside risk. To see Spark’s full report on COSM stock, click here. More about Cosmos Holdings YTD Price Performance: -1.00% Average Trading Volume: 737,875 Technical Sentiment Signal: Strong Sell Current Market Cap: $19.63M</div>

Cosmos Holdings CEO Grigorios Siokas purchased 353,321 shares of the company's stock, valued at $173,127, indicating strong confidence in its future. The company reported growth in its Greek subsidiary, Cosmofarm, and a new manufacturing agreement with Libytec Pharmaceutical. However, TipRanks' AI Analyst rates COSM as an Underperform due to weak financials and bearish technicals, with a current market cap of $19.63M and a year-to-date price performance of -1.00%.

Tip Ranks

VanEck Pharmaceutical ETF

iShares Biotechnology ETF

iShares US Pharma

iShares US Medical Devices

iShares Global Healthcare

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Cosmos Health

Health Care Select Sector SPDR

VG Health

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

SPDR Pharmac

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bear 3X

SPDR S&P Health Equip

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Invesco Pharmaceuticals ETF

Cosmos CEO Makes Bold Move With Fresh Stake in the Company’s Stock